CTOs on the Move

Helix Medical Communication

www.helixhh.com

 
Helix Medical Communication is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.helixhh.com
  • 1200 Us Highway 22
    Bridgewater, NJ USA 08807
  • Phone: 908.203.1010

Executives

Name Title Contact Details

Similar Companies

Runatek

At Runatek, were ending the Opioid Crisis with innovative technology

Cannon Building Services Inc

Cannon Building Services Inc is a Placentia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brookwood Pharmaceuticals

Brookwood Pharmaceuticals is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Goodness Growth

Goodness Growth Holdings, Inc. is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. Today, the Company is licensed to grow, process, and/or distribute cannabis in four markets and operates 14 dispensaries in three states.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.